{"id":"corticosteroids-rivaroxaban","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (rivaroxaban-related)"},{"rate":null,"effect":"Infection risk (corticosteroid-related)"},{"rate":null,"effect":"Hyperglycemia (corticosteroid-related)"},{"rate":null,"effect":"Osteoporosis (corticosteroid-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids work by binding glucocorticoid receptors to reduce inflammatory cytokine production and immune cell activation. Rivaroxaban is a direct Factor Xa inhibitor that blocks the intrinsic and extrinsic coagulation pathways. Together, this combination addresses both inflammatory and thrombotic components of disease, likely in a condition where both pathways contribute to pathology.","oneSentence":"This combination uses corticosteroids to suppress inflammation and immune responses while rivaroxaban prevents blood clots by inhibiting Factor Xa in the coagulation cascade.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:46.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 investigational combination therapy (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06780462","phase":"PHASE3","title":"Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-15","conditions":"Behcet Syndrome","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Corticosteroids + Rivaroxaban","genericName":"Corticosteroids + Rivaroxaban","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Corticosteroids are being studied in combination with Rivaroxaban for the treatment of Deep Venous Thrombosis in Behcet Syndrome, as part of a randomized controlled multicenter study. This study is comparing the effectiveness of corticosteroids alone versus corticosteroids plus Rivaroxaban in treating Deep Venous Thrombosis in patients with Behcet Syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}